Market revenue in 2023 | USD 96.3 million |
Market revenue in 2030 | USD 163.1 million |
Growth rate | 7.8% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data | 2021 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Danaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the South Korea mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
South Korean CDMOs and pharmaceutical companies have formed strategic partnerships with global leaders in the mRNA field. These partnerships often involve technology transfer and collaboration agreements, which accelerate the development and production of mRNA-based therapeutics.
This has enhanced the country’s mRNA manufacturing capabilities and reputation. CDMOs have made significant investments in state-of-the-art manufacturing facilities equipped for mRNA production. These facilities adhere to international quality standards and can cater to both domestic and global markets.
For example, in May 2021, Samsung Biologics—a leading company in the South Korean mRNA therapeutics contract development and manufacturing market—partnered with Moderna to provide large-scale, commercial fill-finish manufacturing for the latter’s mRNA-1273 COVID-19 vaccine.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into South Korea mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account